2018 American Transplant Congress » Poster Session C: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Date: Monday, June 4, 2018

Time: 6:00pm-7:00pm

Location: Hall 4EF

Session Type: Poster Session

Meeting: 2018 American Transplant Congress

6:00pm-7:00pm: β-Glucuronidase Gene Expression in Stool Samples Associated with Chronic Allograft Dysfunction in Kidney Transplants

A. Israni,^1,2 D. Knights,³ G. Al-Ghalith,³ A. Muthusamy,² B. Wu,⁴ W. Oetting,⁵ D. Schaldt,² R. Remmel,⁵ P. Jacobson,⁵ For DeKAF Genomics & GEN03 Investigators.¹

6:00pm-7:00pm: 12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients

M. Matignon,¹ C. Dudreuilh,¹ P. Rémy,¹ J-.L. Taupin,² P. Grimbert.¹

6:00pm-7:00pm: A Novel Combined Formula to Direct Optimal Immunosuppressive Drug Exposure in Renal Transplant Recipients

O. Pankewycz,¹ E. Onan,² M. Laftavi,¹ R. Gruessner,³ H. Smileuski,¹ E. Alissandrello,¹ A. Gruessner.³

6:00pm-7:00pm: A Novel Protocol to Improve Kidney Transplant Outcomes in Patients with Renal Disease Due to Amyloidosis

A. Langone, B. Concepcion, D. Slosky, R. Cornell, S. Horst, S. Goodman.

6:00pm-7:00pm: Assessment of Peak Levels and Metabolism Rates in African American (AA) and Non-AA Kidney Transplant Recipients (KTR) on Immediate-Release Tacrolimus (IR-tac)

T. Horwedel,¹ R. Sodhi,² D. Tsapapas,³ M. Mills,⁴ S. Patel,⁴ G. Towns.⁵

6:00pm-7:00pm: Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation

A. Dao, S. Tremblay, A. Shields, A. Loethen, B. Abu Jawdeh, T. Diwan, A. Govil, E. Woodle, R. Alloway.

6:00pm-7:00pm: CMV and BKV Infections after Kidney Transplantation: Combined Tacrolimus/everolimus Strategy Using Antithymocyte Globulin Induction

T. Jouve,^1,4 R. Germi,^2,4 B. Janbon,¹ G. Fiard,^3,4 P. Malvezzi,¹ L. Rostaing.^1,4

6:00pm-7:00pm: Calcineurin Inhibitors, Macrolides, and the Risk of Adverse Drug Events in Kidney Transplant Recipients

R. Jeong,¹ R. Quinn,² P. Ravani,² K. Lentine,³ A. Lloyd,¹ B. Hemmelgarn,² K. Wen,¹ B. Braam,¹ S. Gourishankar,¹ A. Wong,¹ N. Lam.¹

6:00pm-7:00pm: Can We Optimise Immunosuppression Strategies in Our Older Renal Transplant Recipients?

M. Morton,¹ K. Parker,¹ C. Morecroft.²

6:00pm-7:00pm: Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation

W. Park,^1,2 S. Yeo,¹ S. Kang,^1,2 H. Park,¹ K. Jin,^1,2 S. Park,^1,2 S. Han.^1,2

6:00pm-7:00pm: Cognition after Belatacept Conversion

C. Ogbejesi, E. Cohen, K. Belfield, W. Asch.

6:00pm-7:00pm: Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients- 3 Years Follow-Up

S. Narumi,¹ Y. Watarai,¹ N. Goto,² T. Hiramitsu,¹ M. Tsujita,² M. Okada,¹ K. Futamura,² T. Kobayashi.³

6:00pm-7:00pm: Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients

M. Benincasa,¹ V. Colomy,¹ N. Sifontis,¹ S. Rao,² K. Lau,³ S. Karhadkar,³ A. Di Carlo,³ A. Diamond.⁴

6:00pm-7:00pm: De Novo or Early Conversion to Everolimus and the Risk of Skin Cancers in Kidney Transplant Recipients: A Trial-Based Linkage Study

T. Ying,^1,2 G. Wong, W. Lim, G. Russ, H. Pilmore, J. Kanellis, D. Goodman, P. Trevillian, S. Campbell, M. Suranyi, M. Mathew, R. Faull, R. Masterson, R. Walker, P. O'Connell, S. Chadban.^1,2

6:00pm-7:00pm: Development of Optimal Simplified Equation for Estimation of Mycophenolic Acid Exposure Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients

W. Peng, C. Tian, Z. Chen, W. Xue, G. Wang, Q. Ye, X. Zhang, M. Gu, M. Zhao, C. Wang, C. Huang, J. Yan, W. Zhang, C. Ding, Y. Fu, S. Ye, X. Hu, R. Tan, M. Li, R. Deng, Y. Ke, W. Wu, M. Fan, J. Chen.

6:00pm-7:00pm: Does One Size Fit All? Implementing a Protocolized Ambulatory Tacrolimus Dosing Strategy in a Predominantly African American Renal Transplant Population

L. Gylten, C. Mardis, D. Taber, H. Meadows, C. Perez, Z. Elmaasarani, J. Fleming, N. Patel, P. Baliga, V. Rao, V. Rohan, N. Pilch.

6:00pm-7:00pm: Early Conversion to a CNI-Free Immunosuppression with SRL after Renal Tx – 10 yr Follow-Up Analysis of a Prospective Multicenter Trial

J. Andrassy,¹ M. Guba,¹ A. Habicht,² M. Fischereder,³ A. Pascher,⁴ K. Heller,⁵ B. Banas,⁶ O. Hakenberg,⁷ T. Vogel,⁸ T. Kauke.¹

6:00pm-7:00pm: Early Steroid Withdrawal or Tacrolimus Minimization versus Standard Immunosuppression in Renal Transplant Recipients: The Allegro Trial

J. Sanders,¹ A. Gomes-Neto,¹ M. v Dijk,¹ M. v Sandwijk,² H. de Fijter,³ J. Homan vd Heide,² A. de Vries,³ F. Bemelman.²

6:00pm-7:00pm: Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study

M. Matignon,¹ C. Dudreuilh,¹ P. Rémy,¹ D. Desvaux,² P. Grimbert.¹

6:00pm-7:00pm: Effect of De Novo Use of Everolimus with Reduced Calcineurin Inhibitor versus Standard Mycophenolic Acid-Based Regimen on Wound Healing Events in Kidney Transplant Recipients from TRANSFORM Study

M. Henry, F. Citterio, M. Kim, D. Kim, P. Bernhardt, A. Gupta, Y. Watarai.

6:00pm-7:00pm: Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant

Y. Lu,¹ J. Lyons,² S. Tischer,² K. Woodside,³ J. Park.²

6:00pm-7:00pm: Evaluation of Multiple Linear Regression Limited Sampling Strategies for Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients

C. Staatz,¹ E. Brooks,¹ N. Isbel,² B. McWhinney,³ S. Tett.¹

6:00pm-7:00pm: Evaluation of Tacrolimus Extended-Release in African American Renal Transplant Recipients

T. Sparkes, B. Ravichandran, C. Williams, B. Thomas, B. Masters.

6:00pm-7:00pm: Everolimus and the Risk of Graft Loss or Death in Kidney Transplant Recipients: A Trial-Based Linkage Study

T. Ying,^1,2 G. Wong, W. Lim, G. Russ, H. Pilmore, J. Kanellis, D. Goodman, P. Trevillian, S. Campbell, M. Suranyi, M. Mathew, R. Faull, R. Masterson, R. Walker, P. O'Connell, S. Chadban.^1,2

6:00pm-7:00pm: Identification of Novel Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant Recipients Using Next Generation Sequencing

C. Dorr,^1,2,3 B. Wu,² R. Remmel,² A. Muthusamy,¹ D. Schladt,¹ J. Abrahante,² W. Guan,² R. Mannon,⁴ A. Matas,² W. Oetting,² P. Jacobson,² A. Israni.^1,2,3

6:00pm-7:00pm: Immunosuppression Does Not Affect Adverse Pathological Outcomes in Men Who Underwent Radical Prostatectomy

M. Eltemamy, A. Elshafei, Y. Nyame, A. Crane, A. Wee, V. Krishnamurthi, E. Klein, S. Jones.

6:00pm-7:00pm: Impact of Steroid Maintenance on the Outcomes of HLA-DR Mismatch Kidney Transplantation

B. Chopra, K. Sureshkumar.

6:00pm-7:00pm: Improved Value with Individualized Antithymocyte Globulin Dosing Protocol in Renal Transplant

J. Dann, W. Ally, M. Bradley, J. Geyston, A. Agarwal.

6:00pm-7:00pm: Influence of Trough Level in Tacrolimus on the Appearance Rate of De Novo Donor Specific Antibody (dnDSA) under Low Dose-Based Tacrolimus Protocol during 7 Years Follow-Up after Renal Transplantation

H. Ishida,¹ K. Tanabe,² T. Shimizu,¹ M. Furusawa.²

6:00pm-7:00pm: Late Conversion from Calcineurin Inhibitors to Belatacept is Associated with a Sustained Improvement in Kidney Allograft Function

S. Sethi, J. Choi, A. Vo, R. Najjar, A. Peng, S. Jordan, E. Huang.

6:00pm-7:00pm: Long Term Outcomes of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant

Y. Kassis,¹ S. Park,¹ A. Shetty,¹ J. Leventhal,¹ V. Mas,² L. Gallon.¹

6:00pm-7:00pm: Long-Term Effects of Ketoconazole in Rapid Tacrolimus Metabolizers Post-Renal Transplantation

J. Ching,¹ S. Anders,¹ M. Janusek,¹ L. Hutchinson,¹ A. Freeman,¹ U. Patel,¹ A. Mohammed,⁴ H. Bohorquez.^2,3

6:00pm-7:00pm: Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 9 Years Follow-Up

S. Narumi,¹ Y. Watarai,¹ N. Goto,² T. Hiramitsu,¹ M. Okada,¹ M. Tsujita,² K. Futamura,² M. Nishihira,³ T. Kobayashi.⁴

6:00pm-7:00pm: Long-Term Outcomes of a Steroid-Free, Belatacept-Based Immunosuppressive Regimen Plus Sirolimus Using Alentuzumab Induction in Renal Transplantation

A. Guasch,¹ A. Ghali,¹ S. Mead,¹ A. Mehta,¹ H. Xu,² A. Kirk.²

6:00pm-7:00pm: MeltDose Prolonged-Release Once-Daily Tacrolimus (LCPT) vs. Conventional Tacrolimus Formulations in the Initial Maintenance of De Novo Kideny Transplant Recipients across Europe: STEADY Study

K. Budde,¹ G. Piotti,² C. Procaccianti,³ G. Nicolini,³ S. Geraci,³ D. Surace.³

6:00pm-7:00pm: Mycophenolate Monotherapy is Safe and Effective in HLA-Matched Kidney Transplant Recipients

A. Hennes, K. Holdener, W. Burlingham, B. Astor, A. Djamali.

6:00pm-7:00pm: Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation

J. Dann, W. Ally, M. Bradley, J. Geyston, A. Agarwal.

6:00pm-7:00pm: Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection

Y. Matsuoka,¹ K. Iwasaki,² Y. Miwa,² K. Horimi,¹ K. Uchida,² T. Kobayashi.¹

6:00pm-7:00pm: Once-Daily MeltDose Tacrolimus Formulation and Renal Function in Caucasian Fast Tacrolimus Metabolizers: Does Early Identification Have an Impact in PK Sensitive Patients?

K. Budde,⁶ B. Suwelack,¹ D. Stevens,³ W. Du,⁴ C. Procaccianti,⁵ C. Maas,⁵ S. Bunnapradist.²

6:00pm-7:00pm: Outcomes of Early Steroid Withdrawal in 6-Antigen Human Leukocyte Antigen (HLA)-Matched Kidney Transplant Recipients

H. Champion, K. Holdener, B. Astor, F. Aziz, D. Mandelbrot.

6:00pm-7:00pm: Pharmacokinetics of Mycophenolic Acid Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients

W. Peng, C. Tian, Z. Chen, W. Xue, G. Wang, Q. Ye, X. Zhang, M. Gu, M. Zhao, C. Wang, C. Huang, J. Yan, W. Zhang, C. Ding, Y. Fu, S. Ye, X. Hu, R. Tan, M. Li, R. Deng, Y. Ke, W. Wu, M. Fan, J. Chen.

6:00pm-7:00pm: Preemptive Plasma Therapy and Eculizumab (ECU) Rescue for Atypical Hemolytic Uremic Syndrome (aHUS) Relapse Following Kidney Transplantation (KTX)

C. Aigner,^1,2 G. Böhmig,¹ F. Eskandary,¹ M. Gaggl,¹ R. Kain,² R. Sunder-Plassmann,³ Z. Prohaszka,⁴ A. Schmidt,¹ G. Sunder-Plassmann.¹

6:00pm-7:00pm: Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept

M. Perez-Saez,^1,2 B. Yu,¹ A. Uffing,¹ N. Murakami,¹ J. Azzi,¹ S. El Haji,³ S. Gabardi,³ L. Riella.¹

6:00pm-7:00pm: Prolonged-Release Tacrolimus Dosing in De Novo Kidney Transplantation: Randomized, Open-Label, Pilot Study

Y. Kim,¹ Y. Chiang,² S. Kim,³ M. Kim,⁴ S. Park,⁵ S. Wu,⁶ K. Horita,⁷ Y. Nakashima,⁷ H. Jiang,⁸ D. Han.¹

6:00pm-7:00pm: Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients

S. Lee,¹ K. Huh,² J. Jeon,³ S-.J. Kim,⁴ Y. Kim,² C-.K. Oh.¹

6:00pm-7:00pm: Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis

P. Chen,² L. Nair,² A. Ata,² D. Conti,¹ R. Lopez-Soler.¹

6:00pm-7:00pm: Sirolimus-Based, Prednisone-Free Regimen in Kidney Transplantation: Long Term Results of an Open-Label, Randomized Controlled Trial

A. Shetty,¹ B. Ho,¹ V. Mas,² Y. Kassis,¹ S. Park,¹ J. Leventhal,¹ D. Chhabra,³ L. Gallon.¹

6:00pm-7:00pm: Steroid Avoidance in Renal Transplant Patients Treated with Everolimus and Low-Exposure Tacrolimus

T. Sandes-Freitas,^1,2 M. Sales,¹ J. Oliveira,¹ M. Oliveira,¹ G. Dantas,² C. Girão,¹ R. Esmeraldo.¹

6:00pm-7:00pm: Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients

K. Tornatore,^1,4 K. Attwood,² D. Brazeau,³ S. Chang,⁴ R. Venuto.⁴

6:00pm-7:00pm: The Effect of Tacrolimus Trough Level and Intrapatient Variability on the Transplant Outcomes in Kidney Transplantation

J. Lee,¹ J. Lee,¹ Y. Jung,¹ D. Kim,¹ S. Song,² J. Lee,³ J. Lee,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ B. Kim,⁴ K. Huh.¹

6:00pm-7:00pm: The Infusion with a Difference: Patient Experiences with Belatacept

H. Murad, D. Malhotra, E. Cohen, W. Asch.

6:00pm-7:00pm: The Ratio of CTLA4 to Perforin and Granzyme B as a Potential Biomarker of Tolerance in Chimeric Renal Transplant Patients

A. Khalil,¹ A. Chhabra,¹ A. Merchak,¹ L. Kahn,¹ J. Leventhal,² S. Ildstad.¹

6:00pm-7:00pm: Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations in Renal Transplant Recipients

K. Khalil, P. West-Thielke, A. Lichvar, E. Benedetti, S. Patel.

6:00pm-7:00pm: Transplant Cost Reduction in a Developing Country: “The Case of Guatemala”

S. Méndez,¹ B. Remey,² E. Reyes,¹ A. Aguilar-González,¹ R. Lou-Meda.¹

6:00pm-7:00pm: Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients

P. Malvezzi,¹ C. Fischman,² T. Jouve,¹ B. Janbon,¹ P. Heeger,² L. Rostaing,¹ P. Cravedi.²

6:00pm-7:00pm: Validation of Genetic Variants Identified in GWAS for Tacrolimus Troughs

P. Jacobson,¹ D. Schladt,² W. Guan,³ J. van Setten,⁶ R. Remmel,⁴ B. Wu,³ C. Dorr,⁵ B. Keating,⁷ D. Ikle,⁹ R. Mannon,¹⁰ A. Matas,⁸ A. Israni,⁵ W. Oetting.¹

« View all sessions from the 2018 American Transplant Congress